Published in Cancer on April 15, 1980
Effects of combination endocrine treatment on normal prostate, prostatic intraepithelial neoplasia, and prostatic adenocarcinoma. J Clin Pathol (1994) 1.04
Androgen receptor targets NFkappaB and TSP1 to suppress prostate tumor growth in vivo. Int J Cancer (2007) 0.99
Correlation of vascular endothelial growth factor expression with fibroblast growth factor-8 expression and clinico-pathologic parameters in human prostate cancer. Br J Cancer (2001) 0.99
P2-purinergic receptor agonists inhibit the growth of androgen-independent prostate carcinoma cells. J Clin Invest (1992) 0.92
Java Web Start based software for automated quantitative nuclear analysis of prostate cancer and benign prostate hyperplasia. Biomed Eng Online (2005) 0.91
Prostatic carcinoma bilateral iris metastases. Bosn J Basic Med Sci (2012) 0.81
Cyproterone acetate enhances TRAIL-induced androgen-independent prostate cancer cell apoptosis via up-regulation of death receptor 5. BMC Cancer (2017) 0.75
Natural history of progression after PSA elevation following radical prostatectomy. JAMA (1999) 14.35
Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA (1994) 9.15
The development of human benign prostatic hyperplasia with age. J Urol (1984) 8.29
The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N Engl J Med (1992) 7.16
Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA (1992) 6.40
Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am (2001) 5.39
Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science (1996) 5.06
The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol (1993) 4.55
Interpretation of Emergency Department radiographs: a comparison of emergency medicine physicians with radiologists, residents with faculty, and film with digital display. AJR Am J Roentgenol (2000) 4.13
Impotence following radical prostatectomy: insight into etiology and prevention. J Urol (1982) 4.08
Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology (2001) 3.99
Hereditary prostate cancer: epidemiologic and clinical features. J Urol (1993) 3.86
Bilateral Adrenalectomy in Prostatic Cancer: Clinical Features and Urinary Excretion of 17-Ketosteroids and Estrogen. Ann Surg (1945) 3.65
Radical prostatectomy with preservation of sexual function: anatomical and pathological considerations. Prostate (1983) 3.53
Mendelian inheritance of familial prostate cancer. Proc Natl Acad Sci U S A (1992) 3.28
Family history and the risk of prostate cancer. Prostate (1990) 3.27
Using prostate-specific antigen to diagnose prostate cancer: sailing in uncharted waters. Ann Intern Med (1993) 2.77
New radiographic grading scales for osteoarthritis of the hand. Reliability for determining prevalence and progression. Arthritis Rheum (1989) 2.77
Characteristics of prostate cancer in families potentially linked to the hereditary prostate cancer 1 (HPC1) locus. JAMA (1997) 2.73
Comparison of magnetic resonance imaging and ultrasonography in staging early prostate cancer. Results of a multi-institutional cooperative trial. N Engl J Med (1990) 2.67
Predicting femoral neck strength from bone mineral data. A structural approach. Invest Radiol (1990) 2.55
Correlation of pathologic findings with progression after radical retropubic prostatectomy. Cancer (1993) 2.40
Prognostic significance of Gleason score 3+4 versus Gleason score 4+3 tumor at radical prostatectomy. Urology (2000) 2.35
Era specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer. J Urol (2001) 2.32
Familial incomplete male pseudohermaphroditism, type 2. Decreased dihydrotestosterone formation in pseudovaginal perineoscrotal hypospadias. N Engl J Med (1974) 2.27
A comparison of patients and patient complaints at six chiropractic college teaching clinics. J Manipulative Physiol Ther (1989) 2.20
Distribution of metastatic sites in renal cell carcinoma: a population-based analysis. Ann Oncol (2011) 2.18
Normal age-related patterns of cellular and fatty bone marrow distribution in the axial skeleton: MR imaging study. Radiology (1990) 2.13
A prospective comparison of radical retropubic and robot-assisted prostatectomy: experience in one institution. BJU Int (2003) 2.13
Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. Urol Clin North Am (1997) 2.07
Transthoracic needle aspiration biopsy of benign and malignant lung lesions. AJR Am J Roentgenol (1985) 2.05
Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomy. Urology (1995) 2.00
Prediction of progression following radical prostatectomy. A multivariate analysis of 721 men with long-term follow-up. Am J Surg Pathol (1996) 1.98
A case of TdT-positive B-cell acute lymphoblastic leukemia. Am J Clin Pathol (1986) 1.97
Homozygous deletion and frequent allelic loss of chromosome 8p22 loci in human prostate cancer. Cancer Res (1993) 1.96
The association of body weight, body fatness and body fat distribution with osteoarthritis of the knee: data from the Baltimore Longitudinal Study of Aging. J Rheumatol (1995) 1.86
Association of radiographic features of osteoarthritis of the knee with knee pain: data from the Baltimore Longitudinal Study of Aging. Arthritis Care Res (1995) 1.85
Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy. J Urol (1988) 1.81
CT evaluation of amyloidosis: spectrum of disease. Radiographics (1993) 1.77
The influence of hormonal therapy on survival of men with advanced prostatic cancer. J Urol (1982) 1.70
Nonpalpable stage T1c prostate cancer: prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings. J Urol (1998) 1.69
Implication of cell kinetic changes during the progression of human prostatic cancer. Clin Cancer Res (1995) 1.68
Genetic susceptibility of benign prostatic hyperplasia. J Urol (1994) 1.66
Management of stage D1 adenocarcinoma of the prostate: the Johns Hopkins experience 1974 to 1987. J Urol (1990) 1.65
Radical prostatectomy and cystoprostatectomy with preservation of potency. Results using a new nerve-sparing technique. Br J Urol (1984) 1.63
Sexual function following radical prostatectomy: influence of preservation of neurovascular bundles. J Urol (1991) 1.63
An anatomical approach to the surgical management of the dorsal vein and Santorini's plexus during radical retropubic surgery. J Urol (1979) 1.63
Cystic lesions of the prostate gland. A sonographic--pathologic correlation. J Ultrasound Med (1990) 1.61
Biological aggressiveness of hereditary prostate cancer: long-term evaluation following radical prostatectomy. J Urol (1998) 1.60
Precise localization of the autonomic nerves from the pelvic plexus to the corpora cavernosa: a detailed anatomical study of the adult male pelvis. J Urol (1985) 1.58
Cavernous nerve grafts restore erectile function in denervated rats. J Urol (1991) 1.57
Cancer control following anatomical radical prostatectomy: an interim report. J Urol (1991) 1.55
The epidemiology of prostate cancer in Jamaica. J Urol (1998) 1.53
Idiopathic retroperitoneal fibrosis. J Urol (1979) 1.53
Disease progression following radical prostatectomy in men with Gleason score 7 tumor. J Urol (1998) 1.50
Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. J Urol (1990) 1.49
Autosomal dominant polycystic kidney disease and pain - a review of the disease from aetiology, evaluation, past surgical treatment options to current practice. J Postgrad Med (2004) 1.46
Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. Urology (1994) 1.45
Serum PSA after anatomic radical prostatectomy. The Johns Hopkins experience after 10 years. Urol Clin North Am (1993) 1.45
Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging. Urology (2000) 1.44
Assay of urinary oxalate: six methodologies compared. Clin Chem (1983) 1.44
Laparoscopy, robot, telesurgery and urology: future perspective. J Postgrad Med (2002) 1.43
Pathological stage is higher in older men with clinical stage B1 adenocarcinoma of the prostate. J Urol (1989) 1.43
Sex differences in geometry of the femoral neck with aging: a structural analysis of bone mineral data. Calcif Tissue Int (1992) 1.41
Impact of anatomical radical prostatectomy on urinary continence. J Urol (1991) 1.41
Linkage and association studies of prostate cancer susceptibility: evidence for linkage at 8p22-23. Am J Hum Genet (2001) 1.40
Immunohistochemical study of androgen receptors in metastatic prostate cancer. Comparison of receptor content and response to hormonal therapy. Cancer (1991) 1.39
Clinical and experimental studies of benign prostatic hyperplasia. Urol Clin North Am (1990) 1.38
Adjuvant radiotherapy after radical prostatectomy: is it indicated? J Urol (1987) 1.38
The induction of prostatic hypertrophy in the dog with androstanediol. J Clin Invest (1976) 1.38
Incidence of TdT positivity in cases of leukemia and lymphoma. Acta Haematol (1986) 1.38
Fatty infiltration of the liver: ultrasonographic and computed tomographic correlation. J Ultrasound Med (1984) 1.37
Ginger: an ethnomedical, chemical and pharmacological review. Drug Metabol Drug Interact (2001) 1.34
Long-term results of radiation therapy for prostate cancer recurrence following radical prostatectomy. J Urol (1998) 1.34
Validation of Partin tables for predicting pathological stage of clinically localized prostate cancer. J Urol (2000) 1.33
Dedifferentiation of prostate cancer grade with time in men followed expectantly for stage T1c disease. J Urol (2001) 1.33
Influence of capsular penetration on progression following radical prostatectomy: a study of 196 cases with long-term followup. J Urol (1993) 1.33
Robotically assisted laparoscopic radical prostatectomy: feasibility study in men. Eur Urol (2001) 1.32
Evaluation of linkage and association of HPC2/ELAC2 in patients with familial or sporadic prostate cancer. Am J Hum Genet (2001) 1.32
Radical prostatectomy with preservation of sexual function: pathological findings in the first 100 cases. J Urol (1985) 1.32
Prospective evaluation of men with stage T1C adenocarcinoma of the prostate. J Urol (1997) 1.32
The role of radical prostatectomy in the management of prostatic cancer. Cancer (1987) 1.32
The incidence of intersexuality in patients with hypospadias and cryptorchidism. J Urol (1976) 1.31
Association of hand and knee osteoarthritis: evidence for a polyarticular disease subset. Ann Rheum Dis (1996) 1.29
Immunohistochemical localization of nitric oxide synthase in the autonomic innervation of the human penis. J Urol (1993) 1.28
Pulmonary hamartoma: CT findings. Radiology (1986) 1.28
Early age at diagnosis in families providing evidence of linkage to the hereditary prostate cancer locus (HPC1) on chromosome 1. Cancer Res (1997) 1.27
Familial aggregation of osteoarthritis: data from the Baltimore Longitudinal Study on Aging. Arthritis Rheum (1998) 1.27
Tissue content of dihydrotestosterone in human prostatic hyperplasis is not supranormal. J Clin Invest (1983) 1.24
Prostatic duct adenocarcinoma. Findings at radical prostatectomy. Cancer (1991) 1.23
The effect of nafarelin acetate, a luteinizing-hormone-releasing hormone agonist, on benign prostatic hyperplasia. N Engl J Med (1987) 1.23
Oxalate toxicity in LLC-PK1 cells: role of free radicals. Kidney Int (1996) 1.22
The influence of reversible androgen deprivation on serum prostate-specific antigen levels in men with benign prostatic hyperplasia. J Urol (1989) 1.20
Comparison of spontaneous and experimentally induced canine prostatic hyperplasia. J Clin Invest (1979) 1.20